Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas. It is the
cancer most commonly associated with various paraneoplastic syndromes, including the …

The purpose of this review was to determine whether imatinib mesylate (STI571, Gleevec)
has a role in the treatment of osteosarcoma. The expression of platelet‐derived growth factor …

E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF
and SCF receptors. In this study, we show the inhibitory activity of E7080 against SCF …

Multiple receptor tyrosine kinases (RTKs), including PDGFR, have been validated as
therapeutic targets in glioblastoma multiforme (GBM), yet inhibitors of RTKs have had limited …

Imatinib and its analogues were successfully synthesized by an improved method in 19.5–
46.2% total yield of six main steps. Pyrimidinyl amine was prepared by the reaction of …

The goal of this study was to characterize the effects of non–small cell lung carcinoma
(NSCLC)-associated mutations in epidermal growth factor receptor (EGFR/ErbB1) and …

Rat C6 glioma is a chemo-resistant experimental brain tumor that is difficult to treat with
various drug combinations. Previous studies suggested that imatinib mesylate (Gleevec) is …

Bcr-Abl oncogene is responsible for the initial phase of chronic myelogenous leukemia
(CML), which is effectively treated by the Bcr-Abl inhibitor imatinib. Over time patients …

Tumor stroma plays an important role in cancer development. In a variety of tumors, such as
breast carcinomas, a desmoplastic response, characterized by stromal fibroblast and …

Imatinib mesylate (imatinib) inhibits the c-Kit-dependent tyrosine kinase activities and highly
effective in the treatment of CML and GIST patients. Although pancreatic cancer is reported …